Navigation Links
Endo Pharmaceuticals and LecTec Settle Patent Dispute
Date:11/11/2009

174; LA for the treatment of early onset puberty in children; and VALSTAR(TM) for the treatment of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable medical risks. The company markets its branded pharmaceutical products to physicians in pain management, urology, endocrinology, oncology, neurology, surgery and primary care. More information, including this and past press releases of Endo Pharmaceuticals, is available at www.endo.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the company's financial position, results of operations, market position, product development and business strategy, as well as estimates of future net sales, future expenses, future net income and future earnings per share. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "intend," "guidance" or similar expressions are forward-looking statements. Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in this press release. These factors include, but are not limited to: the possibility that the acquisition of Indevus is not complementary to Endo; the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and pipeline products; competition in our industry, including for branded and generic products, and in connecti
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
2. Access Pharmaceuticals Provides Update on MuGard Commercial Launch in North America
3. MAP Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
4. Transcept Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference on November 17
5. Vion Pharmaceuticals Reports 2009 Third Quarter and Nine-Month Results
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
7. Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments
8. ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)
9. Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration
10. DUSA Pharmaceuticals to Present at the Merriman Curhan Ford Investor Summit 2009
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... The role of the Medical Science Liaison ... hasn,t changed: face-to-face meetings are seen as the best ... Leaders. Yet at the same time face-to-face ... interaction, field medical teams within the pharmaceutical sector are ... just one of the challenges addressed in " Medical ...
(Date:2/27/2015)... , Feb. 27, 2015  Acsis Inc., the ... serialization solutions, announced today that John DiPalo , ... Supply & Demand Chain Executive 2015 Provider ... who are leading initiatives to help prepare their companies, ... today,s business climate. This year,s list of Provider Pros ...
(Date:2/27/2015)... Pharmaceuticals, Inc. (Nasdaq: ISIS ) today announced ... loss (NOL) guidance and its cash guidance ending the ... financial results were due in large part to the ... from its partners.  Isis, pro forma NOL of $16.3 ... its 2013 NOL of $40.2 million. On a GAAP ...
Breaking Medicine Technology:Improving the Management of MSL Teams to Create Value across a Diverse Set of Customers 2Acsis CSO John DiPalo Named Supply & Demand Chain Executive 2015 Pro to Know 2Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17
... chemotherapy-soaked beads to choke off and kill cancerous ... research being presented at the 21st annual International ... a minimally invasive therapy that takes a two-pronged ... minimally invasive methods to deliver the beads (also ...
... ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), today announced ... solution) has been accepted for review by the U.S. Food ... for Bepreve as an eye drop treatment for ocular itching ... review of ten months and has been given a user ...
Cached Medicine Technology:Chemoembolization Improving as Liver Cancer Treatment 2Chemoembolization Improving as Liver Cancer Treatment 3Chemoembolization Improving as Liver Cancer Treatment 4ISTA Pharmaceuticals' New Drug Application for Bepreve(TM) Accepted for Review by U.S. Food and Drug Administration 2ISTA Pharmaceuticals' New Drug Application for Bepreve(TM) Accepted for Review by U.S. Food and Drug Administration 3
(Date:2/28/2015)... February 28, 2015 In a recent ... of Game Change Athlete Development Services ... about the benefits of athlete development and player engagement ... the unique challenges that athletes face and how off-field ... success. , Fletcher became involved in athlete development issues ...
(Date:2/28/2015)... With their commitment to achieving physical results and ... to their already robust library of oblique exercises. “Rope ... as, is often performed on a stationary piece of ... relatively safe manner and can be performed by individuals ... of “Rope Pulls” is located in the oblique exercises ...
(Date:2/28/2015)... 2015 The Classic Denture Center ... new special. Throughout all of March patients can ... This service can help overall mouth health ... Patients may notice certain symptoms that suggest the denture ... symptoms include: , 1.    Pain, clicking, and popping in the ...
(Date:2/28/2015)... Mew and Company, a Vancouver corporate ... provide business consulting services in addition to a variety ... and succession planning. Company finances are a complicated matter ... top of this, complex Canadian tax laws can make ... a result, Mew and Company works to advise their ...
(Date:2/28/2015)... February 28, 2015 Indosoft Inc ... suite for Asterisk, are pleased to announce the development ... 5.7 and 5.8 versions of Q-Suite, this new version ... a number of new features to the leading edge ... , Q-Suite 5.9 will add features to enhance security ...
Breaking Medicine News(10 mins):Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2
... The American Thoracic Society has released new official ... idiopathic pulmonary fibrosis (IPF). The statement replaces ATS ... in the epidemiology, etiology, diagnosis and management of ... pharmacologic and non-pharmacologic therapies and palliative care. , ...
... HealthDay Reporter , THURSDAY, March 17 (HealthDay News) ... scanners that emit radiation are tiny, experts say, but disagreement ... mass of travelers who pass through them every year. ... of Radiology , radiation experts David J. Brenner and ...
... cartilage implants created using stem cells can only be ... measure before the almost inevitable need for total joint ... are investigating the possibilities of a biologically-engineered synthetic liquid ... by offering a one stop, permanent solution. ...
... to hospital patients, coordinating and providing direct care and delivering it ... that each of its patient-care units has an adequate number of ... of hours nurses work known as the "target level" ... of patients and their need for care. Too many nurses can ...
... HealthDay Reporter , WEDNESDAY, March 16 (HealthDay News) ... a large hospital, more patients died, a new study discovered. ... nursing shortages and cost-cutting, in that the focus should shift ... research, appearing in the March 17 issue of the ...
... HealthDay Reporter , WEDNESDAY, March 16 (HealthDay ... the nuclear complex in Japan did manage to reach ... the unfolding disaster across the Pacific Ocean will make ... of any radioactive plume reaching the United States are ...
Cached Medicine News:Health News:ATS issues joint statement on the treatment of idiopathic pulmonary fibrosis 2Health News:ATS issues joint statement on the treatment of idiopathic pulmonary fibrosis 3Health News:ATS issues joint statement on the treatment of idiopathic pulmonary fibrosis 4Health News:Not Even Experts Agree on Safety of Airport Scanners 2Health News:Not Even Experts Agree on Safety of Airport Scanners 3Health News:Liquid biomaterials take stem cell therapy to new level 2Health News:Risk of hospital patient mortality increases with nurse staffing shortfalls, study finds 2Health News:Risk of hospital patient mortality increases with nurse staffing shortfalls, study finds 3Health News:When Nurse Staffing Drops, Mortality Rates Rise: Study 2Health News:Radiation From Japan's Nuke Disaster Unlikely to Threaten U.S., Experts Say 2Health News:Radiation From Japan's Nuke Disaster Unlikely to Threaten U.S., Experts Say 3Health News:Radiation From Japan's Nuke Disaster Unlikely to Threaten U.S., Experts Say 4
... Integra 400 plus, innovation means 4 ... reaction cuvettes and im-proved operator ergonomics. ... and ease-of-use required for true workload ... possible with only one analytical platform, ...
... Advia 2400 has minimal ... (as low as 2 ... (40 L/hour) thus maximizing ... universal rack handler facilitates ...
Iron FS Ferene for determination of iron in serum. Available with Calibrator: Trucal U and Controls: Trulab N, Trulab P. For automated systems....
Intended for the quantitative determination of iron in serum. Reaction: Endpoint. Wavelength: 595 nm. Linearity: 500 g/dL (89.5 mol/L). Two vials, liquid reagents....
Medicine Products: